Ganoderic acid TR is a broad-spectrum inhibitor of influenza neuraminidases (NAs), particularly H1N1 and H5N1 neuraminidases, with IC50 values of 4.6 and 10.9 μM, respectively.

Ganoderic acid H is a potent antitumour agent, it mediates its biological effects through the inhibition of transcription factors AP-1 and NF-kappaB, resulting in the down-regulation of expression of Cdk4.

Ganoderenic acid D is a natural product isolated from the effective compounds of Ganoderma lucidum extract (GLE). Ganoderenic acid D induces cell cycle arrest and apoptosis and inhibits the proliferation of cancer cells.

Ganoderic acid J is a natural lanostane-type triterpenoid isolated from the medicinal fungus Ganoderma lucidum. Since its initial characterization in 1985, Ganoderic acid J has been identified as a bioactive constituent with potent anti-inflammatory activity. As a representative member of the ganoderic acid family, it plays a critical role in modulating immune cell responses and mitigating inflammation. It serves as a significant molecular probe for investigating the pharmacological mechanisms of fungal secondary metabolites in inflammatory diseases